Fmr LLC Centessa Pharmaceuticals PLC Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Fmr LLC holds 3,826,194 shares of CNTA stock, worth $86.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,826,194

Previous 3,826,194 -0.0%

Holding current value

$86.4 Million

Previous $55 Million 8.62%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$14.38 - $19.03 $2.51 Million - $3.32 Million	174,600 Added 4.78%	3,826,194 $55 Million
Q4 2024 Feb 13, 2025	BUY	$15.04 - $18.67 $11.1 Million - $13.7 Million	735,100 Added 25.2%	3,651,594 $61.2 Million
Q3 2024 Nov 13, 2024	BUY	$8.58 - $16.99 $1.11 Million - $2.2 Million	129,300 Added 4.64%	2,916,494 $46.6 Million
Q2 2023 Aug 11, 2023	BUY	$3.68 - $6.9 $5.73 Million - $10.7 Million	1,556,285 Added 126.43%	2,787,194 $17.3 Million
Q4 2022 Feb 13, 2023	BUY	$3.05 - $4.19 $1.59 Million - $2.19 Million	522,118 Added 73.66%	1,230,909 $3.82 Million
Q3 2022 Nov 10, 2022	BUY	$3.8 - $5.91 $2.65 Million - $4.13 Million	698,491 Added 6781.47%	708,791 $2.85 Million
Q1 2022 May 13, 2022	SELL	$7.45 - $11.59 $625,800 - $973,560	-84,000 Reduced 89.08%	10,300 $92,000
Q4 2021 Feb 14, 2022	SELL	$10.99 - $17.54 $2.95 Million - $4.71 Million	-268,437 Reduced 74.0%	94,300 $1.06 Million
Q3 2021 Nov 15, 2021	SELL	$16.7 - $23.11 $7.14 Million - $9.87 Million	-427,263 Reduced 54.08%	362,737 $6.06 Million
Q2 2021 Aug 13, 2021	BUY	$21.71 - $25.66 $17.2 Million - $20.3 Million	790,000 New	790,000 $17.5 Million

Others Institutions Holding CNTA

# of Institutions

127

Shares Held

122M

Call Options Held

638K

Put Options Held

146K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $2.13B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account